TRAWS PHARMA INC
TRAWNASDAQTrading Snapshot
- Day Range
- $0.17 โ $0.22
- 52-Week Range
- $0.22 โ $3.23
- Volume (shares)
- 381,987
- Avg Volume (shares)
- โ
- Shares Outstanding
- 15.4M
- Next Earnings
- 2027-04-13
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- โ
- P/E Ratio
- โ
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-2.11
- Dividend Yield
- โ
- Dilution (1yr)
- +771.1%
TRAWS PHARMA INC
TRAWAbout TRAWS PHARMA INC
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
โLatest News & Updates

Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights
NEWTOWN, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, โTraws Pharma,โ โTrawsโ or โthe Companyโ), a clinical-stage biopharmaceutical company developing novel therapies for COVID-19 and influenz

Traws Pharma Advances Oral COVID-19, Monthly Flu Antiviral Toward Next Milestones
Traws Pharma Inc. (NASDAQ:TRAW) announced final Phase 2a clinical data for its investigational oral COVID-19 therapy ratutrelvir alongside completed bridging and toxicology studies for its once-monthly influenza candidat

Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVIDยฎ
Ratutrelvir , a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID ยฎ , with no viral rebound through Day 28 and fewer treatment

Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)
Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based o